Role and rationale for the use of milnacipran in the management of fibromyalgia

Figures & data

Figure 1 Percentage of patients with fibromyalgia meeting the 2-measure and 3-measure composite responder criteria at 3 months, observed cases. From Study 1²⁵ and Study 2.²⁶

*P < 0.01; **P ≤ 0.001, vs placebo.

Figure 2 Least squares (LS) mean change from baseline in weekly average 24-hour morning recall pain scores. From Study 2,²⁶ observed cases.

*P < 0.05; †P < 0.01; and §P < 0.001, vs placebo.

Table 1 Additional significant outcomes receiving 3 months of milnacipran treatment

Symptom domain	Outcome measures	Treatment groupsa
Function	SF-36 PCS	100, 200
	SF-36 MCS	200
	SF-36 bodily pain	100, 200
	SF-36 physical functioning	100, 200
	SF-36 energy/vitality	100, 200
	SF-36 role limitations-physical	200
	SF-36 role limitations-emotional	200
	SF-36 general health	200
	SF-36 mental health	200
	SF-36 social functioning	200
Fatigue	MFI total	100, 200
	MFI general fatigue	100, 200
	MFI physical fatigue	100, 200
	MFI mental fatigue	200
	MFI reduced motivation	100, 200
	MFI reduced activity	200
Cognition	MASQ total	200
	MASQ attention	100, 200
	MASQ verbal memory	100, 200

a Treatment groups in pooled analysis of 2 pivotal trials^25,26 demonstrating significant least square mean differences from placebo in change from baseline score (P < 0.05, OC).

Abbreviations: 100, milnacipran 100 mg/day; 200, milnacipran 200 mg/day; MASQ, Multiple Ability Self-Report Questionnaire; MCS, Mental Component Summary; MFI, Multidimensional Fatigue inventory; OC, observed cases; PCS, Physical Component Summary; SF-36, Short Form-36 Health Survey.

MeasePJClauwDJGendreauRMThe efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial [published correction appears in J Rheumatol 2009;36(3):661]J Rheumatol200936239840919132781

 PubMed Web of Science ®Google Scholar

ClauwDJMeasePPalmerRHGendreauRMWangYMilnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial [published correction appears in Clin Ther 2009;31(2):446]Clin Ther200830111988200419108787

 PubMed Web of Science ®Google Scholar